New Formulations of Levothyroxine in the Treatment of Hypothyroidism: Trick or Treat?
The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Abstract
Background: Levothyroxine (LT4) as a medication is used by up to 5.3% of the adult population. For optimal efficacy, the traditional tablet formulation (LT4tab) requires that patients avoid concomitant ingestion with food, drinks, and certain medications, as well as excellent patient compliance. Some comorbidities influence bioavailability of LT4 and may mandate repeated dose adjustments. Summary: New LT4 formulations (soft gel [LT4soft] and liquid [LT4liq]) containing predissolved LT4 are claimed to improve bioavailability, presumably by facilitating absorption. Thus, these formulations may well be more suitable than LT4tab for patients whose daily requirements are subjected to variations in bioavailability. Here, we review the evidence and indications for use of new LT4 formulations and highlight areas of uncertainty that are worthy of further investigation. While bioequivalence is established for LT4soft and LT4liq administered to healthy volunteers compared with LT4tab in pharmacokinetic (PK) studies, therapeutic equivalence of the new formulations seems to be different in several clinical settings. Some evidence suggests that new formulations of LT4 may mitigate against the strict requirements relating to concomitant ingestion with food, drinks, and certain medications, which apply to traditional LT4 tablets. The principal indication is in selected patients with disease fluctuations and intermittent therapies with interfering medications, where the need for frequent dose adjustments and office visits may be diminished. Whether the use of LT4soft or LT4liq in patients with impaired gastric acid secretion results in better control of hypothyroidism than LT4tab remains unclear. Conclusions: The evidence in favor of using LT4soft and LT4liq in clinical practice over LT4tab is weak, and the underlying putative PK mechanisms unclear. Additional studies to investigate these potential benefits, define the cost-effectiveness, and understand the PK mechanisms involved with new LT4 formulations are needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jonklaas, J., Bianco, A. C., Bauer, A. J., Burman, K. D., Cappola, A. R., Celi, F. S., Cooper, D. S., Kim, B. W., Peeters, R. P., Rosenthal, M. S., et al. (2014) · Thyroid® · doi:10.1089/thy.2014.0028 · Cited by 1,928 · cited 1×
“Current guidelines recommend that brand and formulation of LT4 should not be altered, unless there is a clinical indication (32,33).”
Global epidemiology of hyperthyroidism and hypothyroidism
Taylor, P. N., Albrecht, D., Scholz, A., Gutierrez-Buey, G., Lazarus, J. H., Dayan, C. M., & Okosieme, O. E. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2018.18 · Cited by 1,552
A review of disintegration mechanisms and measurement techniques
Markl, D., & Zeitler, J. A. (2017) · Pharmaceutical Research · doi:10.1007/s11095-017-2129-z · Cited by 439 · cited 1×
“Excipients are major determinants of disintegration and dissolution (12,17,18).”
Thyroxine in Goiter, Helicobacter pylori Infection, and Chronic Gastritis
Centanni, M., Gargano, L., Canettieri, G., Viceconti, N., Franchi, A., Fave, G. D., & Annibale, B. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa043903 · Cited by 329 · cited 3×
“Patients with stable comorbidities can be managed with higher than average doses of LT4tab (21,104).”
Feller, M., Snel, M., Moutzouri, E., Bauer, D. C., de Montmollin, M., Aujesky, D., Ford, I., Gussekloo, J., Kearney, P. M., Mooijaart, S., et al. (2018) · JAMA · doi:10.1001/jama.2018.13770 · Cited by 266 · cited 1×
“While biochemical euthyroidism (normal serum thyrotropin [TSH]) can be achieved in patients treated with levothyroxine (LT4), quality of life (QoL) may not be restored (8,9).”
Hadlow, N. C., Rothacker, K. M., Wardrop, R., Brown, S. J., Lim, E. M., & Walsh, J. P. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4223 · Cited by 203
Altered intestinal absorption of L-thyroxine caused by coffee
Benvenga, S., Bartolone, L., Pappalardo, M. A., Russo, A., Lapa, D., Giorgianni, G., Saraceno, G., & Trimarchi, F. (2008) · Thyroid · doi:10.1089/thy.2007.0222 · Cited by 191 · cited 1×
“PPI potency, dosage, and routes of administration as well as the different LT4tabs containing different excipients may account for these Clinical studies showed reduced efficacy of LT4tab when taken with PPIs (21,74,90), calcium (63,86), iron (63), se-velamer (99), and espresso coffee (50,73,98).”
Gastrointestinal malabsorption of thyroxine
Virili, C., Antonelli, A., Santaguida, M. G., Benvenga, S., & Centanni, M. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00168 · Cited by 164 · cited 3×
“‘‘Refractory’’ hypothyroidism may be caused by gastrointestinal diseases and interfering medications (12,13).”
Winther, K. H., Cramon, P., Watt, T., Bjorner, J. B., Ekholm, O., Feldt-Rasmussen, U., Groenvold, M., Rasmussen, Å. K., Hegedüs, L., & Bonnema, S. J. (2016) · PLOS ONE · doi:10.1371/journal.pone.0156925 · Cited by 152 · cited 1×
“While biochemical euthyroidism (normal serum thyrotropin [TSH]) can be achieved in patients treated with levothyroxine (LT4), quality of life (QoL) may not be restored (8,9).”
Self-citationAspects of the absorption of oral L-thyroxine in normal man
Wenzel, K. W., & Kirschsieper, H. E. (1977) · Metabolism · doi:10.1016/0026-0495(77)90121-4 · Cited by 151 · cited 2×
“Decreased dissolution may result from raised gastric pH due to antacids, proton pump inhibitors (PPIs), atrophic gastritis, Helicobacter pylori infection (21), delayed gastric emptying (22), food, and drinks other than plain water (23,24).”
Lillevang-Johansen, M., Abrahamsen, B., Jørgensen, H. L., Brix, T. H., & Hegedüs, L. (2018) · Thyroid · doi:10.1089/thy.2017.0517 · Cited by 150
Self-citationLocalization of human thyroxine absorption
HAYS, M. T. (1991) · Thyroid · doi:10.1089/thy.1991.1.241 · Cited by 138 · cited 1×
“The principal sites of LT4 absorption are duodenum and jejunum (26), while ileum is important following bariatric surgery (27).”
Factors Affecting Gastrointestinal Absorption of Levothyroxine: A Review
Skelin, M., Lucijanić, T., Amidžić Klarić, D., Rešić, A., Bakula, M., Liberati-Čizmek, A.-M., Gharib, H., & Rahelić, D. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.01.005 · Cited by 133
Effects of Evening vs Morning Levothyroxine Intake: A Randomized Double-blind Crossover Trial
Bolk, N. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.436 · Cited by 128 · cited 1×
“In many cases, this can be addressed by moving the timing of LT4tab administration to bedtime (92).”
Pabla, D., Akhlaghi, F., & Zia, H. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.10.008 · Cited by 124 · cited 1×
“LT4soft has a gelatin shell, which melts in gastric fluid, thus enabling its LT4 content, predissolved in glycerol, to release into the gastrointestinal fluid and remain in solution regardless of pH (25).”
REICHLIN, S., & UTIGER, R. D. (1967) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-27-2-251 · Cited by 114 · cited 1×
“The explanation may be the linear-logarithmic relationship (37,38) between fT4 and TSH, although the curve is not strictly linear (39).”
Atypical celiac disease as cause of increased need for thyroxine: a systematic study
Virili, C., Bassotti, G., Santaguida, M. G., Iuorio, R., Del Duca, S. C., Mercuri, V., Picarelli, A., Gargiulo, P., Gargano, L., & Centanni, M. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1851 · Cited by 114
Diagnosis and management of treatment-refractory hypothyroidism: an expert consensus report
Centanni, M., Benvenga, S., & Sachmechi, I. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-017-0706-y · Cited by 113 · cited 1×
“Dose adjustments may be triggered by patient non-adherence, concomitant medications, gastrointestinal co-morbidities, switching between generic and branded LT4 products, diet, and alterations in body weight (10).”
Sachmechi, I., Reich, D. M., Aninyei, M., Wibowo, F., Gupta, G., & Kim, P. J. (2007) · Endocrine Practice · doi:10.4158/ep.13.4.345 · Cited by 112 · cited 1×
“PPI potency, dosage, and routes of administration as well as the different LT4tabs containing different excipients may account for these Clinical studies showed reduced efficacy of LT4tab when taken with PPIs (21,74,90), calcium (63,86), iron (63), se-velamer (99), and espresso coffee (50,73,98).”
Lillevang-Johansen, M., Abrahamsen, B., Jørgensen, H. L., Brix, T. H., & Hegedüs, L. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0006 · Cited by 100
Self-citationVita, R., Saraceno, G., Trimarchi, F., & Benvenga, S. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2684 · Cited by 99
Thvilum, M., Brandt, F., Almind, D., Christensen, K., Brix, T. H., & Hegedüs, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075789 · Cited by 92
Self-citationVita, R., Saraceno, G., Trimarchi, F., & Benvenga, S. (2013) · Endocrine · doi:10.1007/s12020-012-9772-2 · Cited by 91 · cited 2×
“However, these studies (63,73,74,86) were small ( n = 8–40), retrospective (74), open-label (63,73,74,86), and better compliance with LT4liq/LT4soft cannot be excluded (63,73,74,86), and the clinical significance of the LT4soft impact was doubtful (86).”
l-Thyroxine Requirement in Patients with Autoimmune Hypothyroidism and Parietal Cell Antibodies
Checchi, S., Montanaro, A., Pasqui, L., Ciuoli, C., De Palo, V., Chiappetta, M. C., & Pacini, F. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1544 · Cited by 89
Fallahi, P., Ferrari, S. M., Camastra, S., Politti, U., Ruffilli, I., Vita, R., Navarra, G., Benvenga, S., & Antonelli, A. (2017) · Obesity Surgery · doi:10.1007/s11695-016-2247-4 · Cited by 81 · cited 2×
“Three studies (59,71,79) were single-patient case reports, three (58,67,68) were small ( n = 6–17 patients), unblinded observational studies, and patient nonadherence before switching to LT4liq cannot be ruled out for all of them.”
Cappelli, C., Pirola, I., Daffini, L., Formenti, A., Iacobello, C., Cristiano, A., Gandossi, E., Agabiti Rosei, E., & Castellano, M. (2016) · Thyroid · doi:10.1089/thy.2015.0422 · Cited by 80
Absorption of Levothyroxine When Coadministered with Various Calcium Formulations
Zamfirescu, I., & Carlson, H. E. (2011) · Thyroid · doi:10.1089/thy.2010.0296 · Cited by 76
Systematic appraisal of lactose intolerance as cause of increased need for oral thyroxine
Cellini, M., Santaguida, M. G., Gatto, I., Virili, C., Del Duca, S. C., Brusca, N., Capriello, S., Gargano, L., & Centanni, M. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1217 · Cited by 72 · cited 1×
“Patients with stable comorbidities can be managed with higher than average doses of LT4tab (21,104).”
Kinetics of degradation of levothyroxine in aqueous solution and in solid state
Won, C. M. (1992) · Pharmaceutical Research · doi:10.1023/a:1018952415732 · Cited by 69
Cassio, A., Monti, S., Rizzello, A., Bettocchi, I., Baronio, F., D'Addabbo, G., Bal, M. O., & Balsamo, A. (2013) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2012.11.070 · Cited by 68
Benhadi, N., Fliers, E., Visser, T. J., Reitsma, J. B., & Wiersinga, W. M. (2010) · European Journal of Endocrinology · doi:10.1530/eje-09-0655 · Cited by 66 · cited 1×
“The explanation may be the linear-logarithmic relationship (37,38) between fT4 and TSH, although the curve is not strictly linear (39).”
L-Thyroxine Absorption in Patients with Short Bowel
STONE, E., LEITER, L. A., LAMBERT, J. R., SILVERBERG, J. D. H., JEEJEEBHOY, K. N., & BURROW, G. N. (1984) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-59-1-139 · Cited by 66 · cited 1×
“Bariatric surgery (excluding sleeve gastrectomy) (28), short bowel syndrome (29), and small intestinal diseases can impair absorption of LT4.”
Peroni, E., Vigone, M. C., Mora, S., Bassi, L. A., Pozzi, C., Passoni, A., & Weber, G. (2014) · Hormone Research in Paediatrics · doi:10.1159/000356047 · Cited by 63
Vita, R., & Benvenga, S. (2014) · Endocrine Practice · doi:10.4158/ep13316.cr · Cited by 60
Improved Levothyroxine Pharmacokinetics After Bariatric Surgery
Gkotsina, M., Michalaki, M., Mamali, I., Markantes, G., Sakellaropoulos, G. C., Kalfarentzos, F., Vagenakis, A. G., & Markou, K. B. (2013) · Thyroid · doi:10.1089/thy.2011.0526 · Cited by 57
Guglielmi, R., Grimaldi, F., Negro, R., Frasoldati, A., Misischi, I., Graziano, F., Cipri, C., Guastamacchia, E., Triggiani, V., & Papini, E. (2018) · Endocrine, Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530318666180125155348 · Cited by 57 · cited 10×
“LT4liq and LT4soft are considerably more expensive than LT4tab, and in the absence of cost-effectiveness data, clinicians ought to be prudent about their use.”
InfluentialSelf-citationThe economic impact of levothyroxine dose adjustments: the CONTROL HE study
Ernst, F. R., Barr, P., Elmor, R., Sandulli, W., Thevathasan, L., Sterman, A. B., Goldenberg, J., & Vora, K. (2017) · Clinical Drug Investigation · doi:10.1007/s40261-016-0462-3 · Cited by 53
Fallahi, P., Ferrari, S. M., & Antonelli, A. (2016) · Endocrine · doi:10.1007/s12020-015-0836-y · Cited by 53
Use of Thyroid Hormones in Hypothyroid and Euthyroid Patients; the 2019 Italian Survey
Negro, R., Attanasio, R., Nagy, E. V., Papini, E., Perros, P., & Hegedüs, L. (2020) · European Thyroid Journal · doi:10.1159/000502057 · Cited by 52 · cited 2×
“In view of the considerable number of patients dissatisfied with LT4tab treat-ment, and the increasing demand for combined LT4 and LT3 preparations, there is an urgent need to clarify whether new LT4 formulations may benefit such patients.”
Self-citationBenvenga, S., Di Bari, F., & Vita, R. (2017) · Endocrine · doi:10.1007/s12020-017-1244-2 · Cited by 51 · cited 2×
“However, these studies (63,73,74,86) were small ( n = 8–40), retrospective (74), open-label (63,73,74,86), and better compliance with LT4liq/LT4soft cannot be excluded (63,73,74,86), and the clinical significance of the LT4soft impact was doubtful (86).”
Fallahi, P., Ferrari, S. M., Ruffilli, I., & Antonelli, A. (2016) · BMC Gastroenterology · doi:10.1186/s12876-016-0439-y · Cited by 46
Effect of vitamin C on the absorption of levothyroxine in patients with hypothyroidism and gastritis
Jubiz, W., & Ramirez, M. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-4360 · Cited by 45 · cited 1×
“Vitamin C facilitates LT4 bioavailability (30).”
Colucci, P., D'Angelo, P., Mautone, G., Scarsi, C., & Ducharme, M. P. (2011) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e318217b69f · Cited by 45 · cited 1×
“Comparative PK studies, in euthyroid individuals not receiving other medications, found that LT4tab, LT4liq, and LT4soft meet regulatory criteria for bioequivalence (15,40,42–44); however, they may not be interchangeable in all clinical scenarios.”
Absorption Kinetics of Levothyroxine Is Not Altered by Proton-pump Inhibitor Therapy
Dietrich, J. W., Gieselbrecht, K., Holl, R. W., & Boehm, B. O. (2006) · Hormone and Metabolic Research · doi:10.1055/s-2006-924980 · Cited by 44
Brancato, D., Scorsone, A., Saura, G., Ferrara, L., Di Noto, A., Aiello, V., Fleres, M., & Provenzano, V. (2014) · Endocrine Practice · doi:10.4158/ep13418.or · Cited by 44
Seng Yue, C., Benvenga, S., Scarsi, C., Loprete, L., & Ducharme, M. (2015) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j36p5m · Cited by 41 · cited 1×
“In a randomized comparative study, acute increase in gastric pH induced by intravenous PPI resulted in impaired LT4tab bioavailability compared with LT4soft (47).”
Levothyroxine: therapeutic use and regulatory issues related to bioequivalence
Wartofsky, L. (2002) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.3.6.727 · Cited by 38 · cited 1×
“Given the narrow therapeutic index of LT4 (31), bioequi-valence and therapeutic equivalence between batches and products are important.”
Ribichini, D., Fiorini, G., Repaci, A., Castelli, V., Gatta, L., Vaira, D., & Pasquali, R. (2017) · Endocrine · doi:10.1007/s12020-016-1167-3 · Cited by 35 · cited 2×
“One study (80) was larger ( n = 43), but was unblinded, the two groups were not matched for age and sex, and the differences between LT4liq and LT4tab were subtle and of doubtful clinical importance.”
Impaired Pharmacokinetics of Levothyroxine in Severely Obese Volunteers
Michalaki, M. A., Gkotsina, M. I., Mamali, I., Markantes, G. K., Faltaka, A., Kalfarentzos, F., Vagenakis, A. G., & Markou, K. B. (2011) · Thyroid · doi:10.1089/thy.2010.0149 · Cited by 34
Concurrent milk ingestion decreases absorption of levothyroxine
Chon, D. A., Reisman, T., Weinreb, J. E., Hershman, J. M., & Leung, A. M. (2018) · Thyroid · doi:10.1089/thy.2017.0428 · Cited by 34 · cited 1×
“Decreased dissolution may result from raised gastric pH due to antacids, proton pump inhibitors (PPIs), atrophic gastritis, Helicobacter pylori infection (21), delayed gastric emptying (22), food, and drinks other than plain water (23,24).”
Patients with lactose intolerance absorb liquid levothyroxine better than tablet levothyroxine
Fallahi, P., Ferrari, S. M., Marchi, S., De Bortoli, N., Ruffilli, I., & Antonelli, A. (2017) · Endocrine · doi:10.1007/s12020-016-1090-7 · Cited by 31 · cited 2×
“Three studies (59,71,79) were single-patient case reports, three (58,67,68) were small ( n = 6–17 patients), unblinded observational studies, and patient nonadherence before switching to LT4liq cannot be ruled out for all of them.”
Skelin, M., Lucijanić, T., Liberati-Čizmek, A.-M., Klobučar, S. M., Lucijanić, M., Jakupović, L., Bakula, M., Lončar, J. V., Marušić, S., Matić, T., et al. (2018) · Endocrine · doi:10.1007/s12020-018-1686-1 · Cited by 31
Cappelli, C., Pirola, I., Gandossi, E., Cristiano, A., Daffini, L., Agosti, B., Casella, C., & Castellano, M. (2016) · International Journal of Endocrinology · doi:10.1155/2016/9043450 · Cited by 29
Fliers, E., Demeneix, B., Bhaseen, A., & Brix, T. H. (2018) · European Thyroid Journal · doi:10.1159/000493123 · Cited by 26 · cited 1×
“Current guidelines recommend that brand and formulation of LT4 should not be altered, unless there is a clinical indication (32,33).”
Ciprofloxacin and Rifampin have opposite effects on levothyroxine absorption
Goldberg, A. S., Tirona, R. G., Asher, L. J., Kim, R. B., & Van Uum, S. H. M. (2013) · Thyroid · doi:10.1089/thy.2013.0014 · Cited by 25
Ernst, F. R., Sandulli, W., Elmor, R., Welstead, J., Sterman, A. B., & Lavan, M. (2017) · Drugs in R&D · doi:10.1007/s40268-016-0150-z · Cited by 23
Lombardi, C. P., Bocale, R., Barini, A., Barini, A., D’Amore, A., Boscherini, M., & Bellantone, R. (2017) · Endocrine · doi:10.1007/s12020-016-1003-9 · Cited by 23
Ferrara, R., Ientile, V., Arcoraci, V., Ferrajolo, C., Piccinni, C., Fontana, A., Benvenga, S., & Trifirò, G. (2017) · Endocrine · doi:10.1007/s12020-017-1242-4 · Cited by 23
Tablet formulation of levothyroxine is absorbed less well than powdered levothyroxine
Yamamoto, T. (2003) · Thyroid · doi:10.1089/10507250360731596 · Cited by 21 · cited 1×
“Disintegration of LT4tab may be facilitated by mechanically pulverizing the tablet (19).”
Pirola, I., Gandossi, E., Brancato, D., Marini, F., Cristiano, A., Delbarba, A., Agosti, B., Castellano, M., & Cappelli, C. (2018) · Journal of Endocrinological Investigation · doi:10.1007/s40618-018-0867-3 · Cited by 21
Trimboli, P., Virili, C., Centanni, M., & Giovanella, L. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00118 · Cited by 21
Benvenga, S., Capodicasa, G., & Perelli, S. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00321 · Cited by 18
Is levothyroxine requirement the same for tablet and soft gel formulations?
Di Donna, V., Paragliola, R. M., de Waure, C., Papi, G., Pontecorvi, A., & Corsello, S. M. (2018) · Endocrine · doi:10.1007/s12020-017-1311-8 · Cited by 17
Radaeli, R. D. F., & Diehl, L. A. (2011) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302011000100012 · Cited by 17
Kim, P. J., & Sachmechi, I. (2015) · AACE Clinical Case Reports · doi:10.4158/ep14051.cr · Cited by 14 · cited 1×
“Decreased dissolution may result from raised gastric pH due to antacids, proton pump inhibitors (PPIs), atrophic gastritis, Helicobacter pylori infection (21), delayed gastric emptying (22), food, and drinks other than plain water (23,24).”
Metformin does not suppress serum thyrotropin by increasing levothyroxine absorption
Al-Alusi, M. A., Du, L., Li, N., Yeh, M. W., He, X., Braverman, L. E., & Leung, A. M. (2015) · Thyroid · doi:10.1089/thy.2015.0211 · Cited by 14
Lobasso, A., Nappi, L., Barbieri, L., Peirce, C., Ippolito, S., Arpaia, D., Rossi, F. W., de Paulis, A., & Biondi, B. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00241 · Cited by 14
Al-Numani, D., Scarsi, C., & Ducharme, M. P. (2016) · Int. Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cp202485 · Cited by 12
Morini, E., Catalano, A., Lasco, A., Morabito, N., & Benvenga, S. (2019) · Endocrine · doi:10.1007/s12020-019-01908-x · Cited by 12
Malabsorption of L-T4 due to drip coffee: a case report using predictors of causation
Wegrzyn, N. M. (2016) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2016.02.016 · Cited by 9 · cited 1×
“PPI potency, dosage, and routes of administration as well as the different LT4tabs containing different excipients may account for these Clinical studies showed reduced efficacy of LT4tab when taken with PPIs (21,74,90), calcium (63,86), iron (63), se-velamer (99), and espresso coffee (50,73,98).”
Intestinal absorption and buccal absorption of liquid levothyroxine
Benvenga, S., & Di Bari, F. (2017) · Endocrine · doi:10.1007/s12020-017-1250-4 · Cited by 8 · cited 1×
“Potential absorption sites outside the gastrointestinal tract would be of special importance; buccal or sublingual routes (101) may avoid the need for parenteral administration.”
Cited by
Primary hypothyroidism and quality of life
Hegedüs, L., Bianco, A. C., Jonklaas, J., Pearce, S. H., Weetman, A. P., & Perros, P. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00625-8 · Cited by 144
Self-citationOptimal thyroid hormone replacement
Jonklaas, J. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab031 · Cited by 89
Perros, P., Van Der Feltz‐Cornelis, C., Papini, E., Nagy, E. V., Weetman, A. P., & Hegedüs, L. (2023) · Clinical Endocrinology · doi:10.1111/cen.14473 · Cited by 65
Self-citationRiis, K. R., Frølich, J. S., Hegedüs, L., Negro, R., Attanasio, R., Nagy, E. V., Papini, E., Perros, P., & Bonnema, S. J. (2021) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01555-y · Cited by 37
Self-citationBednarczuk, T., Attanasio, R., Hegedüs, L., Nagy, E. V., Negro, R., Papini, E., Perros, P., & Ruchała, M. (2021) · Endokrynologia Polska · doi:10.5603/ep.a2021.0048 · Cited by 33
Self-citation
Metadata
- Authors
- Nagy, E. V., Perros, P., Papini, E., Katko, M., & Hegedüs, L.
- Venue
- Thyroid
- Publisher
- SAGE Publications
- Published
- 2021-02-01
- Volume
- 31
- Issue
- 2
- Pages
- 193-201
- ISSN
- 1050-7256 (ISSN-L)
- 1557-9077
- OpenAlex
- W3089904299
- Cited by
- 63
- References
- 71
- FWCI
- 7.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.